---
title: "STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295690734.md"
description: "EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T16:26:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295690734.md)
  - [en](https://longbridge.com/en/news/295690734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295690734.md)
generator: "portal-rs"
---

# STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA

EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News](https://longbridge.com/en/news/296264806.md)
- [JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug development](https://longbridge.com/en/news/296396312.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [UNITED: Record AUM and revenue growth in H1 2026, despite lower profitability year-over-year](https://longbridge.com/en/news/296445897.md)
- [Saab targets pre-2030 flight of fighter-like uncrewed demonstrators in next-gen combat R&D](https://longbridge.com/en/news/296679121.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**